Z vad ome fmk

Anisomycin was purchased from NeoCorp (Weilheim, Germany); z-VAD(OMe)-fmk from Enzo Life Sciences (Farmingdale, NY, USA); annexin-V-FITC from BD Bioscience (San Jose, CA, USA); MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), doxorubicin, CCCP (2-[2-(3-chlorophenyl)hydrazinylyidene]propanedinitrile), and propidium iodide (PI) from Sigma (Taufkirchen, Germany); cOmplete™ EASYpacks protease inhibitors cocktail and PhosSTOP™ EASYpacks from Roche (Mannheim, Germany); androgen receptor antagonist enzalutamide from Hycultec GmbH (Beutelsbach, Germany). The MEK inhibitor PD98059 was purchased from Merck Chemicals GmbH (Darmstadt, Germany), ERK1/2 inhibitors FR180204 and SCH772984 from Adooq bioscience (Irvine, CA, USA); PARP inhibitor olaparib JNK1/2 inhibitor SP600125 and p38 inhibitor SB203580 from LC Laboratories (Woburn, MA, USA).

Annexin-V-FITC was purchased from BD Bioscience (San Jose, CA, USA). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and propidium iodide (PI) from Sigma (Taufkirchen, Germany). cOmplete™ EASYpacks protease inhibitors cocktail and PhosSTOP™ EASYpacks – from Roche (Mannheim, Germany). Anisomycin was from NeoCorp (Weilheim, Germany). z-VAD(OMe)-fmk was from Enzo Life Sciences (Farmingdale, NY, USA). H₂O₂ was from Carl Roth (Karlsruhe, Germany). CCCP (2-[2-(3-chlorophenyl)hydrazinylyidene]propanedinitrile) was from Sigma (Taufkirchen, Germany). JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide) was from AdiloGen Life Science (Epalinges, Switzerland). N-acetylcystein was from MedChemExpress (Monmouth Junction, NJ, USA). Primary and secondary antibodies used are listed in Table 1.

Rhizochalinin (Rhiz, rhizochalin aglycon, Figure 1A), was synthesized from rhizochalin through hydrolysis as reported previously [8 (link)]. For in vitro experiments the 2 mM stock solution of Rhiz in DMSO was used. The purity of the compound was verified by HPLC, ¹ H and ¹³ C NMR spectroscopy. Anisomycin and docetaxel (10 mg/mL) were purchased from NeoCorp (Weilheim, Germany), 3-methyladenine and z-VAD(OMe)-fmk from Enzo Life Sciences (Farmingdale, NY, USA). Matrigel was purchased from BD Biosciences (San Jose, CA, USA); MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent, propidium iodide (PI) and chloroquine from Sigma (Taufkirchen, Germany); annexin-V-FITC from BD Bioscience (San Jose, CA, USA); enzalutamide and minoxidil from Selleckchem (Munich, Germany); diazoxide from R&D Systems (Wiesbaden, Germany); bafilomycin A1 and rapamycin from LC Laboratories (Woburn, MA, USA); cabazitaxel (10 mg/mL) was provided by Sanofi (Paris, France). Antibodies used were obtained commercially and are listed in Supplementary information (Supplementary Table S1). The current research was performed according to the Good laboratory practice regulations (GLPs).